These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 8695275)
1. Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells. Hackenberg R; Hannig K; Beck S; Schmidt-Rhode P; Scholz A; Schulz KD Eur J Cancer; 1996 Apr; 32A(4):696-701. PubMed ID: 8695275 [TBL] [Abstract][Full Text] [Related]
2. Effects of progestin antagonists, glucocorticoids and estrogen on progesterone-induced protein secreted by rabbit endometrial stromal cells in culture. Bigsby RM; Everett LM J Steroid Biochem Mol Biol; 1991 Jul; 39(1):27-32. PubMed ID: 2069862 [TBL] [Abstract][Full Text] [Related]
3. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Attardi BJ; Burgenson J; Hild SA; Reel JR; Blye RP Mol Cell Endocrinol; 2002 Feb; 188(1-2):111-23. PubMed ID: 11911951 [TBL] [Abstract][Full Text] [Related]
4. Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells. Hackenberg R; Hofmann J; Hölzel F; Schulz KD J Cancer Res Clin Oncol; 1988; 114(6):593-601. PubMed ID: 2974456 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Bentel JM; Birrell SN; Pickering MA; Holds DJ; Horsfall DJ; Tilley WD Mol Cell Endocrinol; 1999 Aug; 154(1-2):11-20. PubMed ID: 10509795 [TBL] [Abstract][Full Text] [Related]
6. Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays. Markiewicz L; Gurpide E Methods Find Exp Clin Pharmacol; 1997 May; 19(4):215-22. PubMed ID: 9228646 [TBL] [Abstract][Full Text] [Related]
7. Pre-clinical and clinical treatment of breast cancer with antiprogestins. Klijn JG; Setyono-Han B; Sander HJ; Lamberts SW; de Jong FH; Deckers GH; Foekens JA Hum Reprod; 1994 Jun; 9 Suppl 1():181-9. PubMed ID: 7962463 [TBL] [Abstract][Full Text] [Related]
8. The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells. Horwitz KB Endocrinology; 1985 Jun; 116(6):2236-45. PubMed ID: 4039656 [TBL] [Abstract][Full Text] [Related]
9. Antiprogestins and iatrogenic glucocorticoid resistance. Koper JW; Molijn GJ; van Uffelen CJ; Stigter E; Lamberts SW Life Sci; 1997; 60(9):617-24. PubMed ID: 9048964 [TBL] [Abstract][Full Text] [Related]
10. Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. Bocquel MT; Ji J; Ylikomi T; Benhamou B; Vergezac A; Chambon P; Gronemeyer H J Steroid Biochem Mol Biol; 1993 Apr; 45(4):205-15. PubMed ID: 8499329 [TBL] [Abstract][Full Text] [Related]
11. Androgen sensitivity of the new human breast cancer cell line MFM-223. Hackenberg R; Lüttchens S; Hofmann J; Kunzmann R; Hölzel F; Schulz KD Cancer Res; 1991 Oct; 51(20):5722-7. PubMed ID: 1913690 [TBL] [Abstract][Full Text] [Related]
12. Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells. Hackenberg R; Turgetto I; Filmer A; Schulz KD J Steroid Biochem Mol Biol; 1993 Nov; 46(5):597-603. PubMed ID: 8240982 [TBL] [Abstract][Full Text] [Related]
13. Non-genomic effects of progestins--inhibition of cell growth and increased intracellular levels of cyclic nucleotides. Sager G; Ørbo A; Jaeger R; Engström C J Steroid Biochem Mol Biol; 2003 Jan; 84(1):1-8. PubMed ID: 12648518 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. Fuhrmann U; Hess-Stumpp H; Cleve A; Neef G; Schwede W; Hoffmann J; Fritzemeier KH; Chwalisz K J Med Chem; 2000 Dec; 43(26):5010-6. PubMed ID: 11150172 [TBL] [Abstract][Full Text] [Related]
15. The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Lippman M; Bolan G; Huff K Cancer Res; 1976 Dec; 36(12):4610-8. PubMed ID: 1000506 [TBL] [Abstract][Full Text] [Related]
16. Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening. Hartig PC; Bobseine KL; Britt BH; Cardon MC; Lambright CR; Wilson VS; Gray LE Toxicol Sci; 2002 Mar; 66(1):82-90. PubMed ID: 11861975 [TBL] [Abstract][Full Text] [Related]
17. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Poulin R; Baker D; Poirier D; Labrie F Breast Cancer Res Treat; 1989 Mar; 13(2):161-72. PubMed ID: 2525057 [TBL] [Abstract][Full Text] [Related]
18. RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins. Terakawa N; Shimizu I; Tanizawa O; Matsumoto K J Steroid Biochem; 1988 Aug; 31(2):161-6. PubMed ID: 2457133 [TBL] [Abstract][Full Text] [Related]
19. Comparison of antiprogestin stimulation of uterine prostaglandin synthesis in vitro. Brooks J; Holland P; Kelly R Prostaglandins Leukot Essent Fatty Acids; 1990 Jul; 40(3):191-7. PubMed ID: 2402523 [TBL] [Abstract][Full Text] [Related]
20. Interaction of antiandrogen-androgen receptor complexes with DNA and transcription activation. Warriar N; Pagé N; Koutsilieris M; Govindan MV J Steroid Biochem Mol Biol; 1993 Dec; 46(6):699-711. PubMed ID: 8274404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]